Meitav Dash Investments Ltd. boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 186.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 15,310 shares of the biopharmaceutical company’s stock after buying an additional 9,960 shares during the quarter. Meitav Dash Investments Ltd.’s holdings in Gilead Sciences were worth $1,154,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also made changes to their positions in GILD. Buckingham Asset Management LLC raised its position in Gilead Sciences by 2.3% in the first quarter. Buckingham Asset Management LLC now owns 5,911 shares of the biopharmaceutical company’s stock worth $442,000 after acquiring an additional 131 shares during the period. Baldwin Brothers Inc. MA raised its holdings in Gilead Sciences by 63.3% in the 1st quarter. Baldwin Brothers Inc. MA now owns 351 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 136 shares during the period. Institute for Wealth Management LLC. lifted its position in Gilead Sciences by 1.3% during the fourth quarter. Institute for Wealth Management LLC. now owns 11,104 shares of the biopharmaceutical company’s stock valued at $722,000 after purchasing an additional 145 shares in the last quarter. Wright Investors Service Inc. grew its holdings in Gilead Sciences by 0.7% during the first quarter. Wright Investors Service Inc. now owns 21,631 shares of the biopharmaceutical company’s stock valued at $1,617,000 after purchasing an additional 147 shares during the period. Finally, Gemmer Asset Management LLC increased its position in Gilead Sciences by 17.4% in the first quarter. Gemmer Asset Management LLC now owns 992 shares of the biopharmaceutical company’s stock worth $74,000 after buying an additional 147 shares in the last quarter. Institutional investors own 77.34% of the company’s stock.
GILD has been the topic of a number of analyst reports. Sanford C. Bernstein cut Gilead Sciences from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $78.00 to $70.00 in a research report on Thursday, February 6th. SVB Leerink lifted their price target on shares of Gilead Sciences from $68.00 to $85.00 and gave the company a “market perform” rating in a report on Friday, May 1st. Cantor Fitzgerald increased their price objective on shares of Gilead Sciences from $78.00 to $86.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 7th. Mizuho restated a “buy” rating and set a $81.00 target price on shares of Gilead Sciences in a research note on Wednesday, May 13th. Finally, Robert W. Baird reaffirmed a “hold” rating and issued a $75.00 target price on shares of Gilead Sciences in a report on Thursday. Seven analysts have rated the stock with a sell rating, fifteen have issued a hold rating and nine have issued a buy rating to the company’s stock. Gilead Sciences presently has a consensus rating of “Hold” and an average target price of $78.15.
Shares of NASDAQ:GILD traded down $0.16 on Friday, reaching $73.34. The company’s stock had a trading volume of 6,157,451 shares, compared to its average volume of 19,139,120. The company has a 50-day simple moving average of $77.78 and a 200 day simple moving average of $70.16. Gilead Sciences, Inc. has a 52-week low of $60.89 and a 52-week high of $85.97. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.92 and a current ratio of 3.04. The company has a market cap of $92.20 billion, a P/E ratio of 18.85, a PEG ratio of 3.14 and a beta of 0.72.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.68 EPS for the quarter, beating the Zacks’ consensus estimate of $1.57 by $0.11. The firm had revenue of $5.55 billion during the quarter, compared to the consensus estimate of $5.44 billion. Gilead Sciences had a net margin of 21.84% and a return on equity of 35.44%. The firm’s revenue for the quarter was up 5.1% compared to the same quarter last year. During the same quarter last year, the firm earned $1.67 EPS. On average, equities research analysts forecast that Gilead Sciences, Inc. will post 6.34 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, June 29th. Stockholders of record on Friday, June 12th will be paid a $0.68 dividend. This represents a $2.72 annualized dividend and a dividend yield of 3.71%. The ex-dividend date of this dividend is Thursday, June 11th. Gilead Sciences’s payout ratio is 44.30%.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
See Also: Price to Earnings Ratio (PE) Basics
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.